Display Settings:

Format

Send to:

Choose Destination

    Drug Discov Today. 2004 Dec 1;9(23):1003-11.

    Sulfotransferase structural biology and inhibitor discovery.

    Rath VL, Verdugo D, Hemmerich S.

    Thios Pharmaceuticals, 5980 Horton Street, Suite 400, Emeryville, CA 94608, USA. virginia_rath@yahoo.com

    Sulfotransferases catalyze the transfer of a sulfuryl group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to proteins, carbohydrates and small molecules. The sulfotransferases comprise cytosolic and Golgi-resident enzymes; Golgi-resident enzymes represent fertile territory for identifying pharmaceutical targets. Structure-based sequence alignments indicate that the structural fold, and the PAPS-binding site, is conserved between the two classes. Initial efforts to identify sulfotransferase inhibitors by screening kinase inhibitor libraries yielded competitive inhibitors of PAPS with muM IC(50) values. Within particular classes of Golgi-resident sulfotransferases that show tight in vitro specificity, the substrate-binding site might be a suitable drug target, although sulfotransferases are generally assumed to be difficult to inhibit as a result of the expected size and chemical character of the substrate-binding site.

    PMID: 15574316 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read